Clinical Trials on Recurrent Low Grade Astrocytoma

Total 978 results

Case Comprehensive Cancer Center

Active, not recruiting

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Haukeland University Hospital
Northwell Health; University of Bergen; Weill Medical College of Cornell University and other collaborators

Completed

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma (SAS-GKRS)

Glioma | Glioblastoma | Recurrent Glioblastoma

Norway
Beijing Tiantan Hospital

Active, not recruiting

LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

Recurrent Glioblastoma

China
University Hospital Tuebingen
Evomed MedizinService GmbH

Completed

Ketogenic Diet for Recurrent Glioblastoma (ERGO)

Recurrent Glioblastoma

Germany
Sabine Mueller, MD, PhD
National Cancer Institute (NCI); Dana-Farber Cancer Institute; Mithil Prasad... and other collaborators

Recruiting

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (PNOC023)

Glioblastoma | Recurrent Ependymoma | CNS Tumor | Diffuse Midline Glioma (DMG) | Recurrent Malignant Central Nervous System Neoplasm | Spinal Cord Glioma | Central Nervous System Tumor | World Health Organization (WHO) Grade III Glioma

United States, Switzerland
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Probi AB
Lund University

Completed

Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly

Low-grade Inflammation | Increased Intestinal Permeability

Sweden
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

Anaplastic Oligoastrocytoma | Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
University of Pennsylvania

Completed

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

United States
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Hospices Civils de Lyon

Completed

Olaparib in Recurrent IDH-mutant Glioma (OLAGLI)

Recurrent IDH | Mutant High Grade Glioma

France
Saint Thomas Hospital, Panama

Completed

Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions.

LSIL, Low-Grade Squamous Intraepithelial Lesions

Panama
University of Florida

Not yet recruiting

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

Recurrent Glioblastoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab

Recurrent Glioblastoma
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Henan Provincial People's Hospital

Not yet recruiting

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Recurrent Glioblastoma

China
Oslo University Hospital
Institute for Molecular Medicine

Recruiting

Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma (ISM-GBM)

Recurrent Glioblastoma

Norway
Huashan Hospital
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Sunstem Biotechnology Co., Ltd.

Recruiting

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Recurrent Glioblastoma

China
University College, London
GlaxoSmithKline

Withdrawn

Reirradiation and Niraparib in Patients With Recurrent Glioblastoma (RiNG)

Recurrent Glioblastoma
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Parkridge Medical Center

Terminated

Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT

Glioblastoma | GBM | Recurrent GBM

United States
Beijing Sanbo Brain Hospital

Suspended

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Recurrent Glioblastoma

China
Genexine, Inc.

Active, not recruiting

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Recurrent Glioblastoma

Korea, Republic of
PharmAbcine

Terminated

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Recurrent Glioblastoma

Australia, United States
PharmAbcine

Active, not recruiting

TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Recurrent Glioblastoma

Australia
Massachusetts General Hospital
National Cancer Institute (NCI)

Completed

FMISO PET Study of Glioblastoma

Recurrent Glioblastoma

United States
Johann Wolfgang Goethe University Hospital
TAVARLIN (Darmstadt, Germany)

Completed

Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma (ERGO2)

Recurrent Glioblastoma

Germany
Massachusetts General Hospital
National Cancer Institute (NCI)

Completed

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

Recurrent Glioblastoma

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Recurrent/Refractory Glioblastoma

United States
Shandong Cancer Hospital and Institute

Unknown

Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Recurrent Glioblastoma

China
AstraZeneca

Completed

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL)

Recurrent Glioblastoma

United States, Australia, France, United Kingdom, Germany, Netherlands, Canada, Austria, Belgium, Czech Republic
Duke University
Novartis

Withdrawn

A Panobinostat Presurgery (CLBH589C)

Recurrent Glioblastoma

United States
Ulrik Lassen
University of Copenhagen; Boehringer Ingelheim

Completed

BIBF 1120 in Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma

Denmark
University of Zurich

Completed

Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

Recurrent Glioblastoma

Switzerland
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Center for Neurosciences, Tucson
Genentech, Inc.

Completed

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme | Recurrent Gliosarcoma

United States
Maastricht Radiation Oncology

Withdrawn

The Addition of Chloroquine to Chemoradiation for Glioblastoma,

Glioblastoma | Astrocytoma, Grade IV
European Organisation for Research and Treatment...

Completed

Trabectedin for Recurrent Grade II/III Meningioma

Recurrent High Grade Meningioma

Belgium, Netherlands, France, Spain, Germany, United Kingdom, Italy, Norway, Switzerland, Austria
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
The Second Affiliated Hospital of Henan University...
Xuzhou Medical University; Xinqiao Hospital of Chongqing

Unknown

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (MatchCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Patrick Y. Wen, MD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women... and other collaborators

Terminated

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

High Grade Glioma: Glioblastoma (GBM) | High Grade Glioma: Gliosarcoma | Anaplastic Astrocytoma (AA) | Anaplastic Oligodendroglioma (AO) | Mixed Anaplastic Oligoastrocytoma (AOA)

United States
Boston Scientific Corporation

Recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER)

Glioblastoma Multiforme | Recurrent Glioblastoma

United States
Anders Rosendal Korshøj
Odense University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital and other collaborators

Recruiting

Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery) (OptimalTTF-2)

Recurrent Glioblastoma

Denmark
Sun Yat-sen University

Unknown

A Prospective, Open-label, Single-arm Clinical Study

Recurrent Glioblastoma Multiforme

China
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme

United States, Belgium, Australia, Spain, France, Canada
National Cancer Institute (NCI)
M.D. Anderson Cancer Center; Washington University School of Medicine; Merck... and other collaborators

Completed

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Malignant Glioma | Recurrent Glioblastoma

United States

Clinical Trials on Recurrent Low Grade Astrocytoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations